Royalty Pharma to Present at Upcoming Investor Conferences
- S&P 500, Nasdaq post worst weeks since pandemic start as Netflix woes deepen slide
- Netflix (NFLX) Stock Plummets on Weak Guidance to Prompt Several Downgrades to Neutral
- Peloton (PTON) Shares Recover Some Losses in Pre Market After Sharing Preliminary FQ2 Results, Stifel Upgrades to Buy as 'Stock Has Over Corrected'
- Bitcoin (BTC) Price Plunges 6% to Hit 5-Month Lows
- Dollar dips with U.S. Treasury yields but still up for week; bitcoin falls
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
- Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT
- Morgan Stanley’s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 11:00 a.m. EDT
The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Is Investigating CareDx, Talkspace, Renesola, and WeWork and Encourages Investors to Contact the Firm
- Governor Greg Abbott Recognizes Importance of Educational Opportunity by Proclaiming Jan. 23-Jan. 29 "Texas School Choice Week"
- 'Non Fungible Penny' A New Gold Penny of Henry III*
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!